{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T23:12:57Z","timestamp":1773270777837,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T00:00:00Z","timestamp":1647820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T00:00:00Z","timestamp":1647820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"China National Natural Science Funds","doi-asserted-by":"crossref","award":["81970407"],"award-info":[{"award-number":["81970407"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"China National Natural Science Funds","doi-asserted-by":"crossref","award":["82000452"],"award-info":[{"award-number":["82000452"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"China National Natural Science Funds","doi-asserted-by":"crossref","award":["81900426"],"award-info":[{"award-number":["81900426"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Shanghai Sailing Program","award":["20YF1406600"],"award-info":[{"award-number":["20YF1406600"]}]},{"name":"Grants from Shanghai Excellent Academic Leader","award":["19XD1401200"],"award-info":[{"award-number":["19XD1401200"]}]},{"name":"Fudan University \u201cStar of Tomorrow\u201d Famous Doctor Training Project","award":["2019"],"award-info":[{"award-number":["2019"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Backgrounds<\/jats:title>\n                <jats:p>Patients with AICLI constitute a considerable proportion of NO-CLI patients and cannot be treated with surgical or endovascular treatment. Although cell therapy has shown satisfactory results in treating AICLI, research comparing the efficacy of treatment with the 2 kinds of cell products is rare. The aim of this study was to report the 5-year outcomes of a randomized single-blinded noninferiority trial (Number: NCT 02089828) on peripheral blood mononuclear cells (PBMNCs) and purified CD34<jats:sup>+<\/jats:sup> cells (PCCs) transplantation for treating angiitis-induced critical limb ischemia (AICLI).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A randomized single-blinded non-inferiority trial (Number: NCT 02089828) was performed. Fifty patients were randomized 1:1 to the PBMNCs and PCCs groups. Efficacy outcomes, safety outcomes and patients\u2019 work conditions were analyzed. The primary efficacy outcomes included major amputation and total amputation over 60\u00a0months.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>During the 60-month follow-up, 1 patient was lost to follow-up, 1 died, and 2 underwent major amputation. The major amputation-free survival rate (MAFS) was 92.0% (95% confidence interval [CI] 82.0%-100.0%) in the PBMNCs group and 91.7% (95% CI 81.3%-100.0%) in the PCCs group (<jats:italic>P<\/jats:italic>\u2009=\u20090.980). Compared with the PCCs group, the PBMNCs group had a significantly higher 5-year new lesion-free survival rate (100.0% vs. 83.3% [95% CI 69.7\u201399.7%], <jats:italic>P<\/jats:italic>\u2009=\u20090.039). All patients lost their ability to work before transplantation, and the 5-year cumulative return to work (RTW) rates were 88.0% in the PBMNCs group and 76.0% in the PCCs group (<jats:italic>P<\/jats:italic>\u2009=\u20090.085).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The long-term follow-up outcomes of this trial not only demonstrated similar efficacy and safety for the 2 types of autoimplants but also showed a satisfactory cumulative RTW rate in AICLI patients who underwent cell transplantation.<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic>: ClinicalTrials.gov, number NCT 02089828. Registered 14 March 2014, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT02089828\">https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT02089828<\/jats:ext-link>.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13287-022-02804-4","type":"journal-article","created":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T11:03:04Z","timestamp":1647860584000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The peripheral blood mononuclear cells versus purified CD34+ cells transplantation in patients with angiitis-induced critical limb ischemia trial: 5-year outcomes and return to work analysis\u2014a randomized single-blinded non-inferiority trial"],"prefix":"10.1186","volume":"13","author":[{"given":"Hao","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianyue","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yifan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaolang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiyang","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiguo","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3754-2458","authenticated-orcid":false,"given":"Zhihui","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,21]]},"reference":[{"key":"2804_CR1","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1177\/1526602817719283","volume":"24","author":"S Kum","year":"2017","unstructured":"Kum S, Tan Y, Schreve M, et al. Midterm outcomes from a pilot study of percutaneous deep vein arterialization for the treatment of no-option critical limb ischemia. J Endovasc Ther. 2017;24:619\u201326.","journal-title":"J Endovasc Ther"},{"key":"2804_CR2","first-page":"142","volume":"12","author":"J Dormandy","year":"1999","unstructured":"Dormandy J, Heeck L, Vig S. The fate of patients with critical leg ischemia. Semin Vasc Surg. 1999;12:142\u20137.","journal-title":"Semin Vasc Surg"},{"key":"2804_CR3","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.jvs.2010.08.060","volume":"53","author":"H Lawall","year":"2011","unstructured":"Lawall H, Bramlage P, Amann B. Treatment of peripheral arterial disease using stem and progenitor cell therapy. J Vasc Surg. 2011;53:445\u201353.","journal-title":"J Vasc Surg"},{"key":"2804_CR4","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.jvs.2003.08.006","volume":"39","author":"T Ohta","year":"2004","unstructured":"Ohta T, Ishioashi H, Hosaka M, et al. Clinical and social consequences of Buerger disease. J Vasc Surg. 2004;39:176\u201380.","journal-title":"J Vasc Surg"},{"key":"2804_CR5","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1002\/sctm.17-0252","volume":"7","author":"Y Fang","year":"2018","unstructured":"Fang Y, Wei Z, Chen B, et al. A five-year study of the efficacy of purified CD34+ cell therapy for angiitis-induced no-option critical Limb Ischemia. Stem Cells Transl Med. 2018;7:583\u201390.","journal-title":"Stem Cells Transl Med"},{"key":"2804_CR6","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1002\/stem.207","volume":"27","author":"A Kawamoto","year":"2009","unstructured":"Kawamoto A, Katayama M, Handa N, et al. Intramuscular transplantation of G-CSF-mobilized CD34(+) cells in patients with critical limb ischemia: a phase I\/IIa, multicenter, single-blinded, dose-escalation clinical trial. Stem Cells. 2009;27:2857\u201364.","journal-title":"Stem Cells"},{"key":"2804_CR7","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ebiom.2018.08.038","volume":"35","author":"Z Dong","year":"2018","unstructured":"Dong Z, Pan T, Fang Y, et al. Purified CD34 cells versus peripheral blood mononuclear cells in the treatment of angiitis-induced no-option critical limb ischaemia: 12-Month results of a prospective randomised single-blinded non-inferiority trial. EBioMedicine. 2018;35:46\u201357.","journal-title":"EBioMedicine"},{"key":"2804_CR8","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1002\/sctm.20-0033","volume":"10","author":"H Liu","year":"2021","unstructured":"Liu H, Pan T, Fang Y, et al. Three-year outcomes of peripheral blood mononuclear cells vs. purified CD34 cells in the treatment of angiitis-induced no-option critical limb ischemia and a cost-effectiveness assessment: a randomized single-blinded noninferiority trial. Stem Cells Transl Med. 2021;10:647\u201359.","journal-title":"Stem Cells Transl Med"},{"key":"2804_CR9","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/S0895-4356(98)00095-X","volume":"51","author":"S Fukuhara","year":"1998","unstructured":"Fukuhara S, Bito S, Green J, et al. Translation, adaptation, and validation of the SF-36 health survey for use in Japan. J Clin Epidemiol. 1998;51:1037\u201344.","journal-title":"J Clin Epidemiol"},{"key":"2804_CR10","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/S0895-4356(98)00096-1","volume":"51","author":"S Fukuhara","year":"1998","unstructured":"Fukuhara S, Ware JE Jr, Kosinski M, et al. Psychometric and clinical tests of validity of the Japanese SF-36 health survey. J Clin Epidemiol. 1998;51:1045\u201353.","journal-title":"J Clin Epidemiol"},{"key":"2804_CR11","doi-asserted-by":"publisher","first-page":"3154","DOI":"10.1161\/01.CIR.0000134696.08436.65","volume":"109","author":"Y Yoon","year":"2004","unstructured":"Yoon Y, Park J, Tkebuchava T, et al. Unexpected severe calcification after transplantation of bone marrow cells in acute myocardial infarction. Circulation. 2004;109:3154\u20137.","journal-title":"Circulation"},{"key":"2804_CR12","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1161\/CIRCULATIONAHA.105.589937","volume":"114","author":"D You","year":"2006","unstructured":"You D, Waeckel L, Ebrahimian T, et al. Increase in vascular permeability and vasodilation are critical for proangiogenic effects of stem cell therapy. Circulation. 2006;114:328\u201338.","journal-title":"Circulation"},{"issue":"suppl 1","key":"2804_CR13","doi-asserted-by":"publisher","first-page":"S123","DOI":"10.1038\/ncpcardio0430","volume":"3","author":"S Shintani","year":"2006","unstructured":"Shintani S, Kusano K, Ii M, et al. Synergistic effect of combined intramyocardial CD34+ cells and VEGF2 gene therapy after MI. Nat Clin Pract Cardiovasc Med. 2006;3(suppl 1):S123\u20138.","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"2804_CR14","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1161\/CIRCRESAHA.116.310557","volume":"120","author":"P Mathiyalagan","year":"2017","unstructured":"Mathiyalagan P, Liang Y, Kim D, et al. Angiogenic mechanisms of human CD34 stem cell exosomes in the repair of ischemic hindlimb. Circ Res. 2017;120:1466\u201376.","journal-title":"Circ Res"},{"key":"2804_CR15","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1002\/dmrr.2399","volume":"29","author":"M Dubsky","year":"2013","unstructured":"Dubsky M, Jirkovska A, Bem R, et al. Both autologous bone marrow mononuclear cell and peripheral blood progenitor cell therapies similarly improve ischaemia in patients with diabetic foot in comparison with control treatment. Diabetes Metab Res Rev. 2013;29:369\u201376.","journal-title":"Diabetes Metab Res Rev"},{"key":"2804_CR16","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1161\/CIRCULATIONAHA.110.942383","volume":"121","author":"G Piazza","year":"2010","unstructured":"Piazza G, Creager M. Thromboangiitis obliterans. Circulation. 2010;121:1858\u201361.","journal-title":"Circulation"},{"key":"2804_CR17","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/S1078-5884(97)80017-2","volume":"13","author":"T Sasajima","year":"1997","unstructured":"Sasajima T, Kubo Y, Inaba M, et al. Role of infrainguinal bypass in Buerger\u2019s disease: an eighteen-year experience. Eur J Vasc Endovasc Surg. 1997;13:186\u201392.","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"2804_CR18","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1161\/CIRCRESAHA.111.253286","volume":"109","author":"S Sahoo","year":"2011","unstructured":"Sahoo S, Klychko E, Thorne T, et al. Exosomes from human CD34(+) stem cells mediate their proangiogenic paracrine activity. Circ Res. 2011;109:724\u20138.","journal-title":"Circ Res"},{"key":"2804_CR19","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1161\/ATVBAHA.109.198895","volume":"30","author":"AH Kumar","year":"2010","unstructured":"Kumar AH, Caplice NM. Clinical potential of adult vascular progenitor cells. Arterioscler Thromb Vasc Biol. 2010;30:1080\u20137.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2804_CR20","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1161\/CIRCRESAHA.116.310557","volume":"120","author":"P Mathiyalagan","year":"2017","unstructured":"Mathiyalagan P, Liang Y, Kim D, et al. Angiogenicmechanisms of human CD34(+) stem cell exosomes in the repair of ischemic hindlimb. Circ Res. 2017;120:1466\u201376.","journal-title":"Circ Res"},{"key":"2804_CR21","first-page":"501","volume":"21","author":"K Bachelier","year":"2020","unstructured":"Bachelier K, Bergholz C, Friedrich EB. Differentiation potential and functional properties of a CD34-CD133+ subpopulation of endothelial progenitor cells. Mol Med Rep. 2020;21:501\u20137.","journal-title":"Mol Med Rep"},{"issue":"6","key":"2804_CR22","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/j.1365-2648.2008.04820.x","volume":"64","author":"E Brink","year":"2008","unstructured":"Brink E, Br\u00e4ndstr\u00f6m Y, Cliffordsson C, et al. Illness consequences after myocardial infarction: problems with physical functioning and return to work. J Adv Nurs. 2008;64(6):587\u201394.","journal-title":"J Adv Nurs"},{"issue":"2","key":"2804_CR23","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1001\/archinte.1992.00400140121026","volume":"152","author":"K Rost","year":"1992","unstructured":"Rost K, Smith GR. Return to work after an initial myocardial infarction and subsequent emotional distress. Arch Intern Med. 1992;152(2):381\u20135.","journal-title":"Arch Intern Med"}],"container-title":["Stem Cell Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-022-02804-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13287-022-02804-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-022-02804-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T11:09:42Z","timestamp":1647860982000},"score":1,"resource":{"primary":{"URL":"https:\/\/stemcellres.biomedcentral.com\/articles\/10.1186\/s13287-022-02804-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,21]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2804"],"URL":"https:\/\/doi.org\/10.1186\/s13287-022-02804-4","relation":{},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,21]]},"assertion":[{"value":"7 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study design was approved by the Ethics Committee of Zhongshan Hospital, Fudan University, Shanghai, China. All included patients were informed about the nature of the study and gave their written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All patients signed a consent form for their data to be used for research or publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"116"}}